OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Proteomics
(1)
Organisms
Archaea
(1)
Bacteria
(1)
Betaherpesvirinae
(1)
Borrelia
(1)
Botrytis cinerea
(1)
Candida albicans
(1)
Clostridium perfringens
(1)
Cnidaria
(1)
Eukaryota
(1)
Fasciola
(1)
Fungi
(1)
Hepatitis B virus
(1)
Human betaherpesvirus 5
(1)
Influenza C virus
(1)
Japanese encephalitis virus group
(1)
Miscanthus x giganteus
(1)
Mycobacterium tuberculosis
(1)
Orthoflavivirus
(1)
Panicum virgatum
(1)
Platyhelminthes
(1)
Rattus
(1)
Saccharomyces cerevisiae
(1)
Salmonella enterica subsp. enterica
(1)
Schizosaccharomyces pombe
(1)
Severe acute respiratory syndrome coronavirus 2
(1)
Staphylococcus aureus
(1)
Streptococcus pneumoniae
(1)
Toxoplasma gondii
(1)
Tripsacum dactyloides
(1)
Trypanosoma cruzi
(1)
Repository
pride
(1)
Technology Type
Mass Spectrometry
(1)
Shotgun proteomics
(1)
Publication Date
2023
(1)
Release Date
2024
(3)
2023
(2)
2021
(2)
2022
(1)
Lab affiliation
Norwich Medical School, University of East Anglia, United Kingdom
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Burkholderia thailandensis stress response to 12-bis-THA
Examination of the 12-bis-THA stress response in Burkholderia thailandensis strain E555 to investigate its antimicrobial mechanism of action
ORGANISM(S):
Burkholderia thailandensis E555
2023-07-20
|
PXD041456
|
Pride
12-bis-tha
Atp synthase
Mechanisn-of-action
Respiration
Burkholderia
Cite
Reducing surgical site infections in low-income and middle-income countries (FALCON): a pragmatic, multicentre, stratified, randomised controlled trial.
Not available
S-EPMC8586736
|
biostudies-literature
Cite
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
Not available
S-EPMC12056793
|
biostudies-literature
Cite
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903
|
biostudies-literature
Cite
Structures, processes and outcomes between first referral and referral hospitals in low-income and middle-income countries: a secondary preplanned analysis of the FALCON and ChEETAh randomised trials.
Not available
S-EPMC11552540
|
biostudies-literature
Cite
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425
|
biostudies-literature
Cite
Adaptation of the Wound Healing Questionnaire universal-reporter outcome measure for use in global surgery trials (TALON-1 study): mixed-methods study and Rasch analysis.
Not available
S-EPMC10364512
|
biostudies-literature
Cite
Accuracy of the Wound Healing Questionnaire in the diagnosis of surgical-site infection after abdominal surgery in low- and middle-income countries.
Not available
S-EPMC10895408
|
biostudies-literature
Cite
Preliminary model assessing the cost-effectiveness of preoperative chlorhexidine mouthwash at reducing postoperative pneumonia among abdominal surgery patients in South Africa.
Not available
S-EPMC8360544
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
